Mates Sharon's Form 4 filing
Intra-Cellular Therapies, Inc. (ITCI) · filed Sep 19, 2023
- Accession no.
- 0001209191-23-050101
- Filed
- Sep 19, 2023
- Trade date
- Sep 18-19, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $5.39M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mates SharonCIK 0001585699 | Director, Officer (Chairman, President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2023 | Common Stock | SSaleDisposed | −27,468 | $53.55 | −$1,470,911.4 | 1,122,841 | Direct | |
| Sep 18, 2023 | Common Stock | SSaleDisposed | −28,119 | $53.96 | −$1,517,301.24 | 1,094,722 | Direct | |
| Sep 19, 2023 | Common Stock | SSaleDisposed | −44,413 | $54.17 | −$2,405,852.21 | 1,050,309 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.